Calvera presents Phase 2b data for CLV-226 in atopic dermatitis
Investigational antibody met its primary endpoint at week 16, with skin clearance maintained through week 32.
Read more →
Science for longer, healthier lives
Medicines that change what’s possible.
We follow the science to serious diseases where patients still need better options — from cancer to rare genetic conditions.
16medicines on the market
18programs in development
12trials recruiting now
40+countries we serve
Where we focus
Five therapeutic areas
OncologyTargeted medicines and antibody–drug conjugates for hard-to-treat solid tumors and blood cancers.Learn more
ImmunologyPrecision biologics that calm overactive immune pathways in skin, gut and joint disease.Learn more
NeuroscienceNew approaches to neurodegeneration, migraine and mood disorders, guided by human genetics.Learn more
CardiometabolicLong-acting therapies for heart failure, lipid disorders and metabolic disease.Learn more
Rare DiseaseGene and RNA medicines for small patient communities with no approved options.Learn morePipeline
From lab to patients
Investors
CVRT at a glance
$218.94+35.3% 1Y
Q3 2026 revenue$4.58B
Q3 2026 EPS$1.80
Quarterly dividend$1.02
Our medicines
Recently approved
Neuroscience
Rare Disease
Hemaviahevarsiran
Hereditary transthyretin amyloidosis with polyneuropathy
Oncology
Immunology
Newsroom
Latest news
Calvera and Northfield Genomics sign gene therapy manufacturing agreement
Multi-year collaboration expands viral vector capacity for the rare disease pipeline.
Read more →Calvera reports second-quarter 2026 results
Revenue grew 14% on strong demand for Dermavia and Cardelle; full-year outlook raised.
Read more →Clinical trials
Could a clinical trial be right for you?
Search studies by condition, phase and location, and talk with your doctor about taking part.
Careers
Do the most meaningful work of your career.
Join 18,000 colleagues in research, manufacturing and medicine.
See open positions